The Humanigen class action lawsuit seeks to represent purchasers or acquirers of Humanigen, Inc. (NASDAQ: HGEN) securities between May 28, 2021 and July 12, 2022, inclusive (the “Class Period”). The Humanigen class action lawsuit – captioned Pieroni v. Humanigen, Inc., No. 22-cv-05258 (D.N.J.) – charges Humanigen and certain of its top executives with violations of the Securities Exchange Act of 1934.
If you suffered losses in Humanigen stock and wish to serve as lead plaintiff of the Humanigen class action lawsuit, please provide your information here. You can also contact Humanigen Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at [email protected]. Lead plaintiff motions for the Humanigen class action lawsuit must be filed with the court no later than October 25, 2022. If you suffered losses in Humanigen and have questions, please contact Humanigen Stock Loss Lawyer Timothy L. Miles today.
Humanigen’s lead product candidate is its proprietary antibody lenzilumab, which is under development as a treatment for, among other things, cytokine storm associated with COVID-19. Among other trials, Humanigen is investigating lenzilumab for the treatment of hospitalized COVID-19 patients in the ACTIV-5/BET-B study, which is part of a directed public-private partnership with the National Institutes of Health (“NIH”). In May 2021, Humanigen submitted an application to the U.S. Food and Drug Administration (“FDA”) requesting Emergency Use Authorization (“EUA”) for lenzilumab for the treatment of patients hospitalized with COVID-19.
The Humanigen class action lawsuit alleges that defendants failed to disclose that: (i) lenzilumab was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the FDA was unlikely to approve the lenzilumab EUA and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; and (iii) accordingly, lenzilumab’s clinical and commercial prospects were overstated.
On September 9, 2021, Humanigen announced that the FDA had rejected the lenzilumab EUA, advising investors that, “[i]n its letter, [the] FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19.” On this news, Humanigen’s stock price fell more than 47%.
Then, on July 13, 2022, Humanigen disclosed that lenzilumab had failed to show statistical significance on the primary endpoint of the ACTIV-5/BETB study. On this news, Humanigen’s stock price fell by nearly 80%, further damaging investors who suffered losses in Humanigen stock.
Allegations in the Humanigen Class Action Lawsuit
The Lead Plaintiff Process in the Humanigen Class Action Lawsuit
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased and suffered losses in Humanigen stock to seek appointment as lead plaintiff in the Humanigen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit. An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Humanigen stock, and have further questions, contact Humanigen Stock Loss Lawyer Timothy L. Miles today.
How Can a Humanigen Stock Loss Lawyer Help Me?
A Humanigen Stock Loss Lawyer is well-versed in the complex laws that govern the securities industry and litigation. A Humanigen Stock Loss Lawyer focuses on representing individual investors or funds who have been the victims of fraud or who have disputes with investment professionals. Ordinary individual investors, including civil servants, teachers, nurses, and retirees, may need a securities lawyer. In most cases, if they have lost money due to mistakes, incompetence, or fraud by an investment professional. While FINRA, the SEC, and state securities regulators serve a vital role in protecting investors, they simply have too many individuals, firms, and market transactions to monitor to discovery every act of fraud or negligence. Individual investors should consult with a securities lawyer if they have lost money due to fraud or stockbroker misconduct, such as a Humanigen Stock Loss Lawyer who will work to recover the losses you sustained through a Humanigen Class Action lawsuit.
Contact a Humanigen Stock Loss Lawyer if You Suffered Losses in Humanigen Stock
If you suffered losses in Humanigen stock, contact Humanigen stock loss lawyer Timothy L. Miles today about a Humanigen class action lawsuit, and see what a Humanigen Stock Loss Lawyer can do for you.
Timothy L. Miles, Esq.
Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles was recentely selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, and more.
Timothy L. Miles
Hours of Operation